Ipamorelin - Research Profile & Reviews

Research Overview

Ipamorelin is a pentapeptide growth hormone secretagogue developed by Novo Nordisk. It acts as a selective agonist of the ghrelin/GHS receptor (GHS-R1a) to stimulate growth hormone release from the anterior pituitary. Its high selectivity means it promotes GH release without significantly affecting cortisol, prolactin, or ACTH levels, which is a notable advantage over other GH secretagogues.

The mechanism of action involves binding to ghrelin receptors in the pituitary and hypothalamus, triggering a calcium-dependent signaling cascade that results in GH vesicle exocytosis. Ipamorelin produces dose-dependent GH release with a rapid onset and relatively short duration of action, making it suitable for mimicking natural GH pulsatility.

Research has shown that Ipamorelin can increase GH levels comparably to GHRP-6 but with a much cleaner side-effect profile. Studies in both animal models and human subjects have demonstrated its potential benefits for bone density, body composition, and recovery. It is frequently studied in combination with CJC-1295 (without DAC) for synergistic GH release.

Documented Research Effects

Muscle Growth Fat Loss Recovery Sleep Quality Anti-Aging

Dosage & Protocol

Typical Dose Range

200 – 300

mcg per dose

Frequency

2-3x daily

Cycle Length

8-12 weeks

Common Vial Sizes

2 5

Calculate exact draw volumes and reconstitution steps.

Use Calculator

Dosage information is for research reference only. Always follow established research protocols. Not medical advice.

Storage & Handling

Lyophilized Powder

Temperature -20°C

Shelf Life 2+ years

Reconstituted Solution

Temperature 2-8°C

Shelf Life 4-6 weeks

Frequently Asked Questions

Ipamorelin is considered one of the most selective and well-tolerated growth hormone secretagogues available. Unlike GHRP-6 and GHRP-2, it does not significantly increase cortisol, prolactin, or appetite at standard doses. It produces a clean, dose-dependent GH release without the side effects commonly associated with other ghrelin mimetics, making it ideal for long-term use.

The standard research dosage is 200-300 mcg per injection, administered 2-3 times daily via subcutaneous injection. Common protocols include 200 mcg three times daily (morning, post-workout, and before bed) or 300 mcg twice daily (morning and before bed). Total daily dosage typically ranges from 400-900 mcg.

No, Ipamorelin does not cause the intense hunger spikes associated with GHRP-6. While Ipamorelin does activate the ghrelin receptor (GHS-R), it does so with much greater selectivity for GH release and minimal impact on appetite-regulating pathways. Some users may notice a mild increase in appetite, but it is generally subtle and manageable.

Ipamorelin is considered safe for extended use due to its clean side-effect profile. Typical cycles range from 8-12 weeks, though many protocols extend to 6 months or longer. Unlike some other GH secretagogues, desensitization appears to be minimal with Ipamorelin. Some users run it continuously with periodic breaks of 2-4 weeks every 3-6 months.

Community Reviews

All 142 reviews →

No Reviews Yet

Community reviews for Ipamorelin are being collected. Check back soon.